Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) CFO Kevin Brady sold 3,400 shares of Medpace stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $625.24, for a total value of $2,125,816.00. Following the completion of the sale, the chief financial officer directly owned 12,830 shares in the company, valued at $8,021,829.20. This represents a 20.95% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Medpace Trading Down 0.1%
Shares of MEDP stock opened at $620.03 on Tuesday. The company has a market cap of $17.31 billion, a price-to-earnings ratio of 36.34, a price-to-earnings-growth ratio of 2.77 and a beta of 1.15. The stock has a 50 day simple moving average of $553.21 and a 200-day simple moving average of $492.40. Medpace Holdings, Inc. has a 12-month low of $373.00 and a 12-month high of $677.90.
Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million during the quarter, compared to analysts' expectations of $689.51 million. During the same period last year, the firm earned $3.10 EPS. The company's quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of equities analysts have recently issued reports on the stock. BMO Capital Markets increased their price target on shares of Medpace from $400.00 to $600.00 and gave the company a "market perform" rating in a report on Friday, July 24th. Weiss Ratings raised shares of Medpace from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, August 12th. Jefferies Financial Group lowered shares of Medpace from a "buy" rating to a "hold" rating and upped their target price for the stock from $490.00 to $515.00 in a research report on Tuesday, July 7th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and issued a $535.00 target price on shares of Medpace in a report on Thursday, July 23rd. Finally, Barclays set a $600.00 price target on shares of Medpace in a research report on Thursday, July 23rd. Three analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $584.18.
View Our Latest Analysis on Medpace
Institutional Investors Weigh In On Medpace
A number of large investors have recently bought and sold shares of the stock. California State Teachers Retirement System lifted its position in shares of Medpace by 53,619.6% in the second quarter. California State Teachers Retirement System now owns 13,989,649 shares of the company's stock valued at $7,408,778,000 after acquiring an additional 13,963,607 shares in the last quarter. BlackRock Inc. acquired a new position in Medpace in the 2nd quarter valued at about $1,323,047,000. AQR Capital Management LLC lifted its holdings in Medpace by 65.1% in the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company's stock valued at $518,170,000 after purchasing an additional 404,226 shares in the last quarter. Madison Asset Management LLC acquired a new stake in shares of Medpace during the 2nd quarter worth about $128,956,000. Finally, Bank of America Corp DE acquired a new stake in shares of Medpace during the 2nd quarter worth about $116,891,000. Institutional investors and hedge funds own 77.98% of the company's stock.
About Medpace
(
Get Free Report)
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
